Skip to main content

Alfuzosin Side Effects

Medically reviewed by Last updated on Oct 13, 2023.

Applies to alfuzosin: oral tablet extended release.

Serious side effects of Alfuzosin

Along with its needed effects, alfuzosin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking alfuzosin:


Incidence not known

Other side effects of Alfuzosin

Some side effects of alfuzosin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to alfuzosin: oral tablet extended release.

Nervous system

Very common (10% or more): Dizziness (up to 27%), headache (up to 14%), fatigue (up to 14%)

Common (1% to 10%): Syncope, pain

Postmarketing reports: Flushing[Ref]


Very common (10% or more): Upper respiratory tract infection (up to 14%)

Common (1% to 10%): Bronchitis, sinusitis, pharyngitis

Postmarketing reports: Rhinitis[Ref]


Common (1% to 10%): Hypotension or postural hypotension

Postmarketing reports: Tachycardia, chest pain, angina pectoris in patients with preexisting coronary artery disease, atrial fibrillation[Ref]


Common (1% to 10%): Abdominal pain, dyspepsia, constipation, nausea

Postmarketing reports: Diarrhea, vomiting[Ref]


Common (1% to 10%): Impotence

Postmarketing reports: Priapism[Ref]


Frequency not reported: Intraoperative Floppy Iris Syndrome (IFIS) has been observed in some patients undergoing phacoemulsification cataract surgery while being treated with alpha-1 blockers[Ref]


Postmarketing reports: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)[Ref]


Postmarketing reports: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis[Ref]


Postmarketing reports: Thrombocytopenia


Postmarketing reports: Edema


1. (2002) "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc

2. (2003) "Product Information. Uroxatral (alfuzosin)." sanofi-aventis

3. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P (1994) "Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group." Br J Urol, 74, p. 579-84

4. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH (1994) "Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group." Scand J Urol Nephrol Suppl, 157, p. 169-76

5. Qazi HA, Ananthakrishnan K, Manikandan R, Fordham MV (2006) "Stuttering priapism after ingestion of alfuzosin." Urology, 68, 890.e5-6

6. Cerner Multum, Inc. "UK Summary of Product Characteristics."

7. Wang YS, Tay YK, Kwok C (2006) "Toxic epidermal necrolysis caused by alfuzosin, an alpha1-adrenoceptor antagonist." Arch Dermatol, 142, p. 938

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.